You are here: Industry Insights > acquisition

News List

Pfizer successfully completes the acquisition of Therachon europeanpharmaceuticalreview
July 05, 2019
Pharmaceutical company, Pfizer, has announced it has completed the acquisition of Therachon for $340 million.
LEO Pharma completes the acquisition of Bayer’s dermatology business biospectrumasia
July 04, 2019
LEO Pharma has now acquired the global product rights for Bayer's global prescription dermatology business with the exception of Afghanistan and Pakistan
Pfizer Completes Acquisition of Therachon americanpharmaceuticalreview
July 03, 2019
Pfizer announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.
Taisho Pharmaceutical concludes acquisition of UPSA pharmaceutical-technology
July 03, 2019
Taisho Pharmaceutical has completed an acquisition of Bristol-Myers Squibb’s (BMS) UPSA consumer health business, further supporting its self-medication franchise.
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio worldpharmanews
July 02, 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio.
Hanwell Acquired by Ellab americanpharmaceuticalreview
June 26, 2019
Hanwell has announced its acquisition by Denmark based Ellab, a leader in thermal validation solutions for the pharmaceutical, medical and food processing industries.
Biogen completes Nightstar acquisition pharmatimes
June 11, 2019
Biogen has announced that it has completed its acquisition of Sycona’s Nightstar Therapeutics, the clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Catalent closes $1.2bn acquisition of Paragon Bioservices pharmaceutical-technology
May 22, 2019
Catalent has closed an acquisition of viral vector development and gene therapy manufacturing company Paragon Bioservices for $1.2bn.
Catalent Completes Paragon Acquisition contractpharma
May 21, 2019
$1.2 billion deal for gene therapy leader is final.
Fulcrum acquires global rights of investigational drug losmapimod from GSK pharmaceutical-business-review
April 24, 2019
Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page